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Abstract
Background: Fingolimod (FTY720) is the first sphingosine-1-phosphate (S1P) receptor modulator approved for the
treatment of multiple sclerosis. The phosphorylated active metabolite FTY720-phosphate (FTY-P) interferes with
lymphocyte trafficking. In addition, it accumulates in the CNS and reduces brain atrophy in multiple sclerosis (MS),
and neuroprotective effects are hypothesized.
Methods: Human primary astrocytes as well as human astrocytoma cells were stimulated with FTY-P or S1P. We
analyzed gene expression by a genome-wide microarray and validated induced candidate genes by quantitative
PCR (qPCR) and ELISA. To identify the S1P-receptor subtypes involved, we applied a membrane-impermeable S1P
analog (dihydro-S1P), receptor subtype specific agonists and antagonists, as well as RNAi silencing.
Results: FTY-P induced leukemia inhibitory factor (LIF), interleukin 11 (IL11), and heparin-binding EGF-like growth
factor (HBEGF) mRNA, as well as secretion of LIF and IL11 protein. In order to mimic an inflammatory milieu as
observed in active MS lesions, we combined FTY-P application with tumor necrosis factor (TNF). In the presence of
this key inflammatory cytokine, FTY-P synergistically induced LIF, HBEGF, and IL11 mRNA, as well as secretion of LIF
and IL11 protein. TNF itself induced inflammatory, B-cell promoting, and antiviral factors (CXCL10, BAFF, MX1, and
OAS2). Their induction was blocked by FTY-P. After continuous exposure of cells to FTY-P or S1P for up to 7 days,
the extent of induction of neurotrophic factors and the suppression of TNF-induced inflammatory genes declined
but was still detectable. The induction of neurotrophic factors was mediated via surface S1P receptors 1 (S1PR1)
and 3 (S1PR3).
Conclusions: We identified effects of FTY-P on astrocytes, namely induction of neurotrophic mediators (LIF, HBEGF,
and IL11) and inhibition of TNF-induced inflammatory genes (CXCL10, BAFF, MX1, and OAS2). This supports the view
that a part of the effects of fingolimod may be mediated via astrocytes.
Keywords: Fingolimod, Astrocyte, Neuroprotection, Leukemia inhibitory factor, Interleukin 11, Heparin-binding
EGF-like growth factor, B-cell activating factor of the TNF family/TNFSF13b, CXCL10/IP10, MX1, OAS2
Background
Fingolimod (FTY720) reduces relapses, disability pro-
gression, and brain atrophy in patients with relapsing-
remitting multiple sclerosis (MS) [1, 2]. FTY720 is a
synthetic analog to natural sphingosine. Both are rapidly
phosphorylated by sphingosine kinase 1/2 (SPK1/2) in
blood and tissue to the active compounds FTY720-
phosphate (FTY-P) and sphingosine-1-phosphate (S1P).
Inactivation involves reversible dephosphorylation by
two phosphatases, SGPP1 and SGPP2, and degradation
by a lyase, SGPL1. S1P binds to five S1P receptors
(S1PR1-5), but also direct intracellular signaling has
been described [3, 4]. FTY-P is a ligand for four of these
receptors, S1PR1 and S1PR3-5 [5]. S1P receptors are G
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Both FTY-P and S1P are agonists in short-term. While
after S1P binding the receptor is recycled back to the
surface within minutes [6], this is impaired by the alkyl
side chain of FTY-P [7], resulting in receptor downregu-
lation and functional antagonism of FTY-P in lympho-
cytes after prolonged exposure [8]. This leads to blood
lymphopenia, since CCR7+ lymphocytes are no longer
guided from lymphatic tissue to the bloodstream by the
S1P gradient [8]. Lymphocyte trapping in lymphatic or-
gans is considered a main mode of action of FTY720
therapy in MS. However, details of signaling and recep-
tor kinetics may differ in other cell types [7, 9–11].
In addition to its effects in lymphoid organs, FTY720
has, owing to its lipophilic nature, access to and accu-
mulates in the CNS [12], where S1P receptors are
expressed on all brain resident cells [12]. Astrocytes are
the most abundant cell type within the CNS and pre-
dominantly express S1PR1 and S1PR3 [9, 13]. Astrocytes
maintain CNS homeostasis under physiologic condi-
tions, and astrocyte dysfunction perpetuates CNS dis-
eases [14]. In particular, astrocytes are able to produce
neuroprotective messengers and can play a beneficial
role supporting oligodendrocyte and axonal regeneration
[15] but can also secrete inflammatory cytokines and
actively promote CNS inflammation via adaptive and in-
nate mechanisms [16]. In MS, astrocytes produce in-
creased amounts of BAFF and CXCL10, fostering B cells
and recruiting monocytes and T cells [17, 18].
A decisive role of neurodegeneration in MS pathogen-
esis is increasingly being recognized [19]. While focal in-
flammatory activity as the immunological correlate of
relapses can efficiently be reduced by several available
compounds, preventing loss of axons and brain atrophy
is still a therapeutic challenge. Brain atrophy is an inde-
pendent predictor of disability in patients with relapsing-
remitting MS [20, 21] but was reduced during FTY720
treatment by half [1, 22]. In conjunction with in vitro ef-
fects of FTY-P on brain resident cells and an experimental
autoimmune encephalomyelitis (EAE) model with poten-
tial involvement of CNS S1P receptors in the therapeutic
effect of FTY720 [23], the idea of neuroprotection by
FTY720 has been formulated. Neuroprotection may be
the consequence of reduced number and activity of im-
mune cells entering the CNS, or of CNS-intrinsic effects
such as direct protection of neuronal and oligoden-
drocytic integrity and function, or of beneficial ef-
fects mediated indirectly via other CNS resident
cells. For example, fingolimod was shown to block
NO-production induced by S1P or inflammatory cy-
tokines, resulting in inhibition of astrocyte-mediated
neurodegeneration [24].
In this study, we focused on potential neuroprotective
mechanisms of FTY-P exerted via astrocytic S1P receptors.
We observed that FTY-P induced neuroprotective factors
(leukemia inhibitory factor (LIF), interleukin 11 (IL11), and
heparin-binding EGF-like growth factor (HBEGF)), and
suppressed the tumor necrosis factor (TNF)-induced
inflammatory cytokines BAFF and CXCL10 (aka inter-
feron inducible protein-10, IP10) as well as antiviral
proteins like 2′-5′-oligoadenylate synthetase 2 (OAS2)
and myxovirus resistance 1 (MX1). We suggest that
FTY720 modulates the microenvironment in the brain
via effects on astrocytes.
Methods
Cell culture
Human astrocytes of embryonic origin, devoid of microglial
cells or macrophages [25], as well as U373 astrocytoma
cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) (Life Technologies, Darmstadt, Germany) con-
taining 10 % FCS (Biochrom/Merck, Berlin, Germany) and
100 U/ml penicillin and 100 μg/ml streptomycin (Gibco,
Invitrogen). Cells were plated at a concentration of
100,000 cells/ml. Before stimulation, all cells were
switched to serum-free medium (Panserin 401, Pan-
Biotech, Aidenbach, Germany).
All experiments with fetal human neural progenitor
cells derived from striatal brain area were approved by
the ethics committee of the University of Leipzig and
the Technical University of Munich, Germany, in ac-
cordance with all state and federal guidelines. Human
neural striatal progenitor cells (hstrNPCs) were gener-
ated from CNS tissue of spontaneously aborted human
fetuses (gestational weeks 10, 12, and 14) with mother’s
consent as described. Briefly, the human fetal tissue of
gestational weeks 10, 12, and 14 was washed with sterile
Hanks’ balanced salt solution (HBSS) and dissected into
mesencephalic and non-mesencephalic primary tissue
samples. The tissues were mechanically separated into
small pieces, incubated in 0.1 mg/ml papain solution
(Roche), supplemented with 10 μg/ml DNase (Roche)
for 30 min at 37 °C, then washed three times with HBSS
followed by an incubation with 50 μg/ml antipain solu-
tion (Roche) for 30 min at 37 °C. After three further
washing steps, samples were homogenized 20 times by
gentle trituration. Propagation of the cell suspension was
performed in poly-L-ornithine (Sigma-Aldrich) and fi-
bronectin (Chemicon) coated cell culture flasks. The ex-
pansion medium was based on DMEM/Ham’s F12
mixture (PAA, Laboratories) supplemented with 2 %
B27 (Invitrogen), hrEGF, and hrFGF-2 (20 ng/ml, Pepro-
tech). Growth factors were supplemented every other
day. Long-term expansion of the cells (>6 months) was
enabled in reduced atmospheric oxygen (2–3 %). For
passaging, cell detachment was induced by Accutase™
(PAA Laboratories) for 30 min at 37 °C at a confluency
of 80–100 %. For differentiation, cells were plated onto
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pre-coated cell culture dishes. After the cells reached
80–100 % confluency, the medium was exchanged to
Neurobasal medium (Invitrogen, Germany) containing
additives such as B-27 minus-AO supplement (Invitrogen),
Forskolin (Sigma-Aldrich), and db cyclic AMP (Sigma-
Aldrich). The cells were differentiated for 7 days.
Compounds
We used the following reagents: S1P (SL-140; 100 nM,
1 μM; Enzo Life Biosciences), dihydro-S1P (SL-143;
100 nM, 1 μM; Enzo Life Biosciences), FTY-P (B-0721;
1 μM; Echelon Biosciences/Mobitec) (all dissolved in
methanol), W146 (3602; 1, 10 μM; Tocris; in NaOH),
TY52156 (5328, 1, 10 μM; Tocris; in ethanol), SEW-
2871 (H1109D; 1, 10 μM; Biomol; in DMSO), CYM5541
(4897; 1, 10 μM; Tocris; in DMSO), and TNF (R&D
Systems, in PBS). Concentrations of FTY-P and S1P
were chosen according to pilot experiments for optimal
effects on established S1P induced genes, not for
equimolar concentrations of S1P and FTY-P. In all
experiments, vehicle controls with the respective con-
centration of solvents were included to control for re-
moval of autocrine trophic factors and cellular stress.
RNA, cDNA, and qPCR
RNA was isolated using the Qiagen RNeasy Mini Kit
including DNase digestion (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions. cDNA was
prepared using the High Capacity cDNA Archive Kit
(Applied Biosystems, Darmstadt, Germany). Quantitative
PCR (qPCR) was performed on the ABI 7900HT Fast
Real-Time PCR thermocycler (Applied Biosystems) using
the qPCR core kit and uracil N-glycosylase (both from
Eurogentec, Cologne, Germany). For all reactions, the
annealing temperature was 60 °C. We used the following
primer/probes: LIF, IL11, HBEGF, S1PR1-5, OAS2,
SPHK1, SPHK2, SGPL1, SGPP1, LIFR, EGFR, IL11RA
(TaqMan Gene Expression Assays, Applied Biosystems),
BAFF [18], MX1 [26], and CXCL10 [27]. Cyclophilin A
(peptidyl-prolyl isomerase A (PPIA)), glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), and beta-actin (all
Applied Biosystems) were used as housekeeping genes.
To validate the house-keeping genes, we stimulated
human primary astrocytes or human U373 astrocy-
toma cells with FTY-P, S1P, and TNF and determined
expression of PPIA, GAPDH, and beta-actin by quan-
titative PCR using equal amounts of RNA. We found
no relevant regulation of the analyzed house-keeping
genes by any of the applied stimuli, and expression
levels for PPIA and GAPDH were most stable (Additional
file 1: Figure S1). Therefore, PPIA and GAPDH were used
in the subsequent experiments.
Microarray
Screening for FTY-P induced genes was performed on the
Illumina gene expression microarray platform (Illumina,
Munich, Germany). RNA concentration, purity, and
quality were checked on the Nanophotometer (Implen,
Munich, Germany) and the Agilent 2100 Bioanalyzer
(Agilent Technologies, Palo Alto, CA, USA). All samples
had a RNA integrity number ≥9.8. RNA was amplified
and labeled using the TotalPrep RNA Amplification Kit
(Ambion, Houston, TX, USA) and hybridized onto human
12v3 whole genome gene expression arrays following the
manufacturer’s instructions (Illumina).
Fluorescence intensity values were extracted and
computed to beadsummary data by a BeadArray Reader
(Illumina) using the company’s standard parameters.
No additional background correction beyond that done
by Illumina’s standard protocol was performed. The
manufacturer’s built-in controls were analyzed including
hybridization controls and sample-dependent parameters.
Illumina’s recommendations for quality control were
fulfilled. Data was loaded into R [28] using package bea-
darray for all subsequent calculations.
Eleven out of 48,803 probes listed in the annotation
(0.02 %) were not technically sampled in all cRNA prepara-
tions and thus excluded from further analysis (KCNRG,
PDZRN3, HS.575197, LOC648364, INDO, C7ORF27,
RHOBTB1, CMIP, ZNF57, TMEM80, TMPRSS7).
Probe filtering aimed at keeping only array probes
showing fluorescence levels above background. Back-
ground was defined at the median of all array probes for
each individual microarray. Array probes that did not
pass the threshold on any microarray were removed.
Microarray data normalization was performed using the
function vsn (variance stabilizing normalization) from
the Bioconductor [29, 30] package vsn [31].
Differential gene expression analysis was done using
the package limma. Significantly regulated genes were
ranked using an empirical Bayes method (implementa-
tion eBayes from package limma) that uses information
from the ensemble of all samples to estimate the sample
variance for each gene. This approach aims at stabilizing
the statistical analysis, especially for small array num-
bers. Correction for multiple testing was done using the
false discovery rate (FDR) approach by Benjamini and
Hochberg.
ELISA
Supernatants for ELISA were harvested 8–16 h after the
last stimulation. Enzyme-linked immunosorbent assay
(ELISA) of cell culture supernatants was performed on
Maxisorp 96-well plates (Nunc, Wiesbaden, Germany)
using DuoSet ELISA kits for CXCL10, IL11, HBEGF (all
R&D systems, Wiesbaden-Nordenstadt, Germany) and
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LIF (Bender Med Systems, Vienna, Austria) according to
the manufacturer’s instructions.
siRNA
Silencer® Select Validated siRNAs against S1PR1 and
S1PR3 as well as a control siRNA were purchased from
Ambion/Life Technologies. Sequences are listed in Add-
itional file 2: Table S1. siRNAs were transfected at a con-
centration of 2 nM using Lipofectamine RNAimax (Life
Technologies) following the manufacturer’s instructions.
Twenty-four hours after siRNA transfection, cells were
stimulated with FTY-P as indicated. Eight hours later,
supernatant was harvested and ELISA was performed.
Knock-down was validated by quantitative PCR.
NFκB-reporter assay
U373 cells were cotransfected with a firefly luciferase
reporter plasmid and the internal control CMV Renilla
luciferase plasmid. Twenty-four hours later, cells were
treated with increasing concentrations of FTY-P or ve-
hicle control. One hour later, TNF-α was added as indi-
cated, and 8 h later, cells were lysed with passive lysis
buffer (Promega, Mannheim, Germany). Reporter gene
activity was determined using firefly luciferase substrate
(Biozym, Hamburg, Germany) and Renilla luciferase
substrate (Promega), respectively.
Statistics
Statistics and plotting was done with GraphPad Prism
(GraphPad Software, La Jolla, USA) and R [28] by para-
metric and non-parametric tests as appropriate (two-sam-
ple tests or the respective one-sample tests if samples
were tested against normalized control samples). Tests are
indicated in each figure legend. P values of p < 0.05 (*),
p < 0.01 (**), p < 0.001 (***) and p < 0.0001 (****) were
considered statistically significant.
Results
FTY-P induces neuroprotective factors
To identify effects of FTY-P on astrocytes, we stimulated
primary human astrocytes with FTY-P or S1P for 1 and
8 h and analyzed gene expression on the Illumina micro-
array platform. Since in cell culture, sphingosine and
FTY720 are not efficiently phosphorylated like in blood
and brain, we used the pre-phosphorylated compounds
(S1P, FTY-P). We identified a panel of genes induced by
FTY-P and S1P (Additional file 3: Table S2). Fold-
changes of individual mRNAs correlated between stimu-
lation with FTY-P and S1P (p < 2.2κ10−16 for both 1 and
8 h, no gene with significant opposite regulation for
FTY-P vs. S1P), consistent with S1P receptor agonistic
signaling for both ligands (Fig. 1). LIF, HBEGF, and IL11
were among the most upregulated genes after 1 and/or
8 h of stimulation (Fig. 1a). The induction of LIF, IL11,
and HBEGF mRNA in human astrocytes by FTY-P was
confirmed in independent experiments on primary as-
trocytes (Fig. 1b) and human astrocytoma cells by qPCR
(Fig. 1c). ELISA of supernatants demonstrated the in-
duction on the protein level for LIF and IL11 (Fig. 1d),
whereas we were unable to detect HBEGF in any cell
culture supernatant, possibly due to its sticky properties.
In order to determine whether these putative neurotrophic
factors could affect neuronal survival, we determined the
expression of their receptors on in vitro-differentiated
human neural progenitor cells derived from fetal striatal
brain area. We detected high expression of receptors for
LIF (LIFR) and HBEGF (EGFR). The IL11 receptor IL11RA
was also expressed, however at a lower level (Additional
file 4: Figure S2).
FTY-P interacts with TNF signaling
We asked how emerging inflammation in the CNS
might interact with FTY-P-mediated effects on astro-
cytes. We modeled this in vitro by pretreatment of astro-
cytes with FTY-P and subsequent stimulation with TNF
(Fig. 2). The induction of LIF, HBEGF, and IL11 mRNA
by FTY-P was evident also in the presence of TNF, and
the induction of LIF and HBEGF was even increased by
TNF in a dose-dependent manner (Fig. 2a). Also, protein
secretion of LIF and IL11 was induced in the presence
of TNF by FTY-P (Fig. 2b). It was shown previously that
S1P and TNF signaling are interconnected, as TRAF2
(TNFR-associated factor 2, which is part of the signaling
complex of TNFR1) activates SPHK1 and thereby increases
S1P. S1P, on the other hand, is an important factor in TNF
signaling and canonical NFκB activation [4]. To further
elaborate the interaction between FTY-P and TNF, we ana-
lyzed expression of SPHK1, along with the other FTY-P
metabolizing enzymes SPHK2, SGLP1, and SGPP1. We de-
tected no regulation of SPHK2, SGLP1, and SGPP1 expres-
sion by FTY-P or TNF (Additional file 5: Figure S3A). In
contrast, SPHK1 expression was synergistically induced by
FTY-P or S1P in combination with TNF (Additional file 5:
Figure S3A). Further, we asked whether FTY-P has an im-
pact on TNF-mediated NFκB activation. Using a luciferase-
based reporter assay, we did not detect a major influence of
FTY-P on NFκB activation (Additional file 5: Figure S3B).
This is in line with previous work where S1P alone did not
activate NFκB in A7 cells [4] and NFκB was activated by
S1PR2, which is not targeted by FTY-P, in non-astrocytic
cells [32]. S1P and FTY-P did not alter TNFR1 and TNFR2
gene expressions (Additional file 5: Figure S3C).
In summary, we provide further data on potential
interaction points between TNF and S1P receptor signal-
ing and demonstrate that regulation of TNF receptor
mRNA, NFκB activation, and the synergistically induced
SPHK1 is unlikely to mediate the synergistic induction
of neurotrophic factors by TNF and FTY-P.
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Next, we aimed to identify further genes modulated by
FTY-P pretreatment in the context of inflammation.
Using a TaqMan PCR low density array, we found that
the proinflammatory genes CXCL10 (IP10) and B cell
activator of the TNF family (BAFF), as well as the anti-
viral genes MX1 and OAS2 were induced by TNF in as-
trocytes and that this induction was blocked by FTY-P
(data not shown). Subsequent qPCR experiments con-
firmed that pretreatment with FTY-P blocked the induc-
tion of these inflammatory genes (Figs. 3 and 4c).
Effects persist after long-term application of FTY-P
Since in long-term, FTY-P exerts functional antagonistic




Fig. 1 FTY-P induces expression of neurotrophic factors. a Human primary astrocytes were stimulated with FTY-P (1 μM), S1P (0.05 μM), or vehicle
control for 1 and 8 h. Each experimental group consisted of quadruplicate (FTY-P, S1P) or triplicate (vehicle controls) wells per time point. Gene
expression was determined using the Illumina microarray platform. The fold-change of expression by FTY-P and S1P is shown for each gene.
Significance of regulation is indicated by the color (green: significant regulation by FTY-P; blue: significant regulation by S1P; orange: significant
regulation by both; transparent gray: no significant regulation; two-tailed t tests adjusted for multiple comparison by the method by Benjamini &
Hochberg). See also Additional file 2: Table S1 for details. Human primary astrocytes (b) and human U373 astrocytoma cells (c) were stimulated as
in a. b LIF, IL11, and HBEGF expression in human primary astrocytes was determined after 1 and 8 h by qPCR (mean ± SEM of six independent
biological replicates; paired two-tailed t tests). c LIF, IL11, and HBEGF expression in human U373 astrocytoma cells was determined after 8 h by
qPCR (mean ± SEM of seven independent biological replicates; two-tailed Wilcoxon signed rank test). d LIF and IL11 protein secretion from U373
astrocytoma cells was determined by ELISA 8 h after stimulation (boxplots indicate median and first/third quartile of four independent biological
replicates, with whiskers extending to outliers up to 1.5 × interquartile range; one-tailed Wilcoxon rank sum test)
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FTY-P stimulation of astrocytic cells occurs only for
short-term or also after repeated stimulation in long
term. We were able to maintain U373 cells and primary
human astrocytes at good viability at serum-free condi-
tions for up to 1 week. To model continuous exposure
of CNS astrocytes in cell culture, we daily added FTY-P
or S1P in new serum-free medium to the cells for up to
1 week (Fig. 4a). We observed that the extent of induction
of LIF and IL11 mRNA (data not shown) and protein se-
cretion (Fig. 4b), as well as the reduction of TNF-induced
cytokines (Fig. 4c), was less pronounced after prolonged
exposure with FTY-P compared to a short stimulation but
still present after 1 week (FTY-P for 6–7 days: p < 0.057
(trend) for LIF, p < 0.05 for all other factors). Of note, not
only the effect of FTY-P but also that of S1P declined
(Fig. 4).
Neurotrophic mediators are induced via membrane-
bound S1P receptors
In addition to canonical signaling of S1P via the G pro-
tein coupled membrane-bound S1P receptors, direct
intracellular effects independent of these membrane re-
ceptors have been described [4, 33]. In order to test
whether induction of LIF, HBEGF, and IL11 is mediated
by surface S1P receptors, we applied the synthetic analog
dihydro-S1P (DH-S1P), which—in contrast to S1P—can-
not cross the plasma membrane [34]. Like S1P, also DH-
S1P in equimolar concentrations induced LIF, IL11, and
HBEGF, both in the absence and presence of TNF
(Fig. 5a). The slightly lower induction by DH-S1P might
be explained by the lower affinity of DH-S1P vs. S1P for
S1PR1 [35]. Likewise, DH-S1P blocked the TNF-induced
expression of CXCL10, BAFF, MX1, and OAS2 to a
similar extent as S1P (Fig. 5b). We therefore conclude
that direct intracellular signaling irrespective of mem-
brane receptors is not the major pathway for these ef-
fects. The unphosphorylated forms, sphingosine and
FTY720, did not induce any of the tested genes (data
not shown).
S1PR1 and S1PR3 mediate effects of FTY-P on astrocytes
Both primary human astrocytes and U373 astrocytoma
cells expressed predominantly S1PR1 and S1PR3
(Additional file 6: Figure S4), consistent with the litera-
ture [9, 13]. To determine which receptor is primarily in-
volved in mediating the induction of neurotrophic factors
by FTY-P, we followed different approaches. First, we ap-
plied S1PR1 (SEW-2871) and S1PR3 (CYM5541) specific
agonists and compared induction of LIF and IL11 to the
induction observed after stimulation with FTY-P. Here,
we found that only the S1PR3 specific agonist induced LIF
(Fig. 6a, left panel). The S1PR3 agonist also showed syner-
gistic effects with TNF comparable to FTY-P (Fig. 6a, right
panel). Second, we analyzed the effects of S1PR1 (W146)
and S1PR3 (TY52156) specific antagonists. Blockage of
both S1PR1 and S1PR3 signaling resulted in a dose-
dependent reduction of LIF expression, with S1P3 block-
ing being more effective (Fig. 6b, left panel). This effect
was also observed in the presence of TNF (Fig. 6b, right
panel). Third, we applied RNAi silencing using two dif-
ferent siRNAs targeting S1PR1 and S1PR3, respect-
ively. We validated knock-down by qPCR for S1PR1
and S1PR3 (Fig. 6c). Only knock-down of S1PR3 re-
sulted in a reduction of LIF (Fig. 6d, left panel) and
IL11 (Fig. 6d, right panel), while S1PR1 knock-down
did not show any effect.
a b
Fig. 2 FTY-P induces neurotrophic factor also in the presence of TNF.
a Human U373 astrocytoma cells were treated with FTY-P (1 μM) and
1 h later with different concentrations of TNF (0.005 and 0.125 μg/ml).
Expression of LIF, HBEGF, and IL11 was determined 8 h later by qPCR
(values normalized to PPIA and the untreated control samples; mean ±
SEM of seven independent experiments; two-tailed Wilcoxon signed
rank test. b Human U373 astrocytoma cells were treated with FTY-P
(1 μM) or S1P (0.1 μM), and 1 h later with TNF (0.125 μg/ml). LIF and
IL11 were analyzed by ELISA after 8 h of culture (boxplots indicate
median and first/third quartile of four independent biological replicates,
with whiskers extending to outliers up to 1.5 × interquartile
range; one-tailed Wilcoxon rank sum test)
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In summary, using different approaches (specific
agonists, specific antagonists, and RNAi-mediated
gene knock-down), we aimed to dissect the receptors
involved the induction of neurotrophic factors and in
blocking inflammatory cytokines in astrocytes. We
conclude from these experiments that both S1PR1 and
S1PR3 ligations may confer these effects. We cannot
exclude a heterogeneous response of the cultured
cells, since we measured the response of the cultures
and not of single cells.
Conclusions
Induction of neuroprotective mediators by FTY-P
We observed that FTY-P induces LIF, IL11, and HBEGF
gene expressions and LIF and IL11 protein secretions in
human astrocytes, both in absence and presence of the
inflammatory cytokine TNF. Neuroprotective effects
have been attributed to these proteins: LIF protects
neuronal precursor cells in the substantia nigra in a
murine Parkinson’s disease model in vivo [36]. Ischemic
preconditioning in the retina is mediated via LIF recep-
tor in vivo [37]. While high LIF concentrations increase
the number of MBP+ cells in spinal cord explants, but
not myelination/differentiation [38], myelination is en-
hanced in vitro by LIF with an optimum at low concen-
trations [39] in the order of magnitude as observed in
our model after 1 week of continuous stimulation, sug-
gesting that the amount of LIF produced by FTY-P
stimulation is biologically effective. IL11, which belongs
to the IL6 family like LIF and CNTF [40], promotes sur-
vival and maturation of oligodendrocytes and myelin for-
mation in rodent CNS cultures [41, 42] and enhances
survival of oligodendrocytes and neurons in an EAE
model [42]. In addition, IL11 exerts immunoregulatory
effects in rodent EAE [42]. HBEGF has been shown to
restore neurogenesis in neuronal degenerative disorders
and in ischemia induced brain injury [43]. Furthermore,
it can enhance the survival of dopaminergic neurons
[44]. Hence, a neurotrophic capacity of these proteins has
been established previously and their induction by FTY-P
reported in this study suggests a potential role of FTY-P
in neuroprotection. We observed that the endogenous
ligand S1P has principally similar effects inducing neu-
roprotective mediators in astrocytes. Thus, one may
speculate that the pharmacological agent may enhance
Fig. 3 FTY-P blocks TNF-induced expression of proinflammatory and
antiviral factors. Human U373 astrocytoma cells were treated with FTY-P
(1 μM) and 1 h later with different concentrations of TNF (0.005;
0.125 μg/ml). Expression of CXCL10, BAFF, MX1, and OAS2 was
determined 8 h later by qPCR (values normalized to the
untreated control samples; mean ± SEM of seven independent
biological replicates; two-tailed Wilcoxon signed rank test)
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an already existing endogenous feature of the S1P system
in human astrocytes.
Suppression of TNF-induced inflammatory cytokines by
FTY-P
In addition, FTY-P suppressed TNF-induced expression
of inflammatory cytokines (BAFF, CXCL10), which could
likely contribute to its beneficial effect on inflammation.
BAFF and CXCL10 are key mediators in neuroinflamma-
tion: BAFF expression is elevated in MS lesions to levels
observed in lymphatic organs [18]. Staining localized
BAFF to astrocytes and activated astrocytes can produce
greater amounts of bioactive BAFF per cell than acti-
vated macrophages, suggesting that BAFF derived from
astrocytes is quantitatively meaningful [18]. Therefore,
BAFF is thought to be a relevant part of the B-cell fos-
tering environment and to perpetuate the immune re-
sponse observed in the CNS of patients with MS [45]. In
addition, BAFF was reported to bind to rodent neurons
via BAFF-R [46] and NOGO-R [47]. Functional conse-
quences in humans deserve further elaboration. CXCL10
binds to CXCR3 expressed i.a. on many mononuclear
immune cell types. When present in the CNS, it recruits
inflammatory mononuclear cells to the CNS and con-
tributes to EAE pathogenesis [48]. TNF is a prototypic
inflammatory cytokine produced by immune cells and
CNS resident cells in the context of inflammation. TNF
is present in active MS lesions [49], and TNF CSF con-
centrations correlate with disease progression in MS
[50]. Soluble TNF can exert toxic effects directly via
death-domain containing TNFR1 on oligodendrocytes
and neurons [51, 52] and indirectly via astrocytes, which
might then amplify inflammatory signals. Plain TNF
antagonists, however, abolish also protective signaling
for neurons and oligodendrocytes via TNFR2 and pro-
voke or exacerbate MS [53, 54]. Suppressing proinflam-
matory cytokines produced by astrocytes downstream of
TNF circumvents the risks associated with total TNF
blockade [53]. Therefore, this is a perspective to limit
further inflammation without the risk of reducing
TNFR2-mediated protective signals. This constitutes a




Fig. 4 FTY-P effects are detectable also after long-term exposure. a For experiments shown in b and c, cells were switched to serum-free medium
before the experiment. Serum-free cell culture medium was then replaced daily for up to 7 days. For the last n days (orange period), it contained
additional FTY-P or S1P (n is displayed on the X axis in b and c). Thus, the total duration of serum-free cell culture was equal for all conditions per
experiment. b U373 astrocytoma cells were treated with FTY-P (1 μM) or S1P (0.1 μM) for the last 1 and 6 days (one experiment) or the last 1, 4
and 7 days (3 experiments). Supernatants were harvested 8–16 h after the last stimulation. IL11 and LIF were measured by ELISA. Values from the
vehicle control (averages for LIF 7.6 pg/ml, IL11: 2.7 pg/ml) were subtracted from the FTY-P and S1P stimulated cells. Boxplots indicate median
and first/third quartile, with whiskers extending to outliers up to 1.5 × interquartile range; one-tailed Wilcoxon rank sum test. c Human astrocytes
of embryonic origin (triangles) or U373 astrocytoma cells (circles) were stimulated with FTY-P (1 μM) or S1P (0.1 or 1 μM) for the last n days. Multiple
data points per time point represent independent biological replicates. One hour after the last FTY-P application, TNF (0.025 μg/ml) was added. Cell
lysates were harvested 8–16 h after TNF application. BAFF mRNA, CXCL10 mRNA, and CXCL10 protein were determined by qPCR and ELISA. Values of
FTY-P and S1P treated samples are displayed normalized to the samples without FTY-P and S1P (i.e. TNF only = 100 %). Boxplots indicate median and
first/third quartile, with whiskers extending to outliers up to 1.5 × interquartile range; one-sample t tests
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or soluble TNF [55, 56]. In contrast to the inhibition of
TNF-induced CXCL10 demonstrated here, a recent study
did not observe inhibition of CXCL10 induced by IL1β in
astrocytes, but FTY-P was applied only at a much lower
concentration of 0.1 μM [57].
Suppression of antiviral proteins by FTY-P
Adverse events in fingolimod treated patients include
upper respiratory tract infections. Neurotropic herpes
virus infection and reactivation occurred more fre-
quently in the fingolimod-treated patients [22]. MX1
and OAS2 are antiviral proteins that play an important
role in the type I interferon-mediated response against a
broad range of viral infections [58–60]. Blocking of the
antiviral mediators MX1 and OAS2 might extend the
spectrum of immunosuppressive effects of FTY-P be-
yond impaired CCR7+ lymphocyte egress from second-
ary lymphatic organs and impaired antigen shuttling in
the spleen marginal zone [61].
Effects persist during continuous stimulation with FTY-P
Since the main mode of action of FTY-P known in lym-
phocytes is receptor downmodulation and functional
antagonism, we elaborated whether our findings are de-
tectable also during continuous stimulation for up to
1 week. Albeit at a lower level, all effects persisted. Fur-
thermore, there was no fundamental difference between
S1P and FTY-P stimulation, as would be expected in the
case of functional antagonistic effects by FTY-P as op-
posed to agonistic effects by S1P. This suggests that re-
ceptor agonistic signaling is present in long term,
possibly because receptor downmodulation may be in-
complete and partially compensated by persistent signal-
ing after internalization [7, 9]. In line with this concept,
also repeated application of FTY-P for 3 days results in
sustained inhibition of intracellular calcium release by
IL1β in human astrocytes. In fact, profound differences
regarding S1PR1 expression, regulation, and signaling
between lymphocytes and other cell types have been
described: lymphocyte recirculation was suggested to be
“exquisitely sensitive” [10] to receptor downmodulation
as opposed to other cell types. Reasons might include
lower surface expression of S1P1R [10] and a higher
threshold of occupancy needed for cellular activation
[11] in lymphocytes. In addition, e.g., endothelial cells,
but not lymphocytes, have a substantial intracellular re-
serve of S1P1R, allowing for more continuous signaling
[11]. Taken together, the sustained induction of neuro-
trophic factors and suppression of inflammatory genes
in astrocytes by repeated application of FTY-P is in line
with different signaling and receptor kinetics in different
cell types.
Receptors involved
Using a ligand that cannot cross the cell membrane
(DH-S1P) [34], we excluded the possibility that induction
of neurotrophic factors and reduction of inflammatory
a b
Fig. 5 Induction of LIF, HBEGF, and IL11, as well as suppression of
CXCL10, BAFF, MX1 and OAS2 is mediated via membrane receptors
and not via direct intracellular signaling of S1P. Human U373
astrocytoma cells were treated with S1P (1 μM; can cross the cell
membrane) or DH-S1P (1 μM; cannot cross the cell membrane) and
1 h later with TNF (0.025 μg/ml). Eight hours later, expression of a LIF,
HBEGF, IL11, b CXCL10, BAFF, MX1, and OAS2 was determined by qPCR
(values normalized to PPIA and the untreated control samples; mean ±
SEM of five independent biological replicates; one-sample two-tailed
t test for comparison with the unstimulated cells (normalized to a value
of 1), two-sample two-tailed paired t test for comparison between other
groups). Both S1P and the non-membrane-permeable derivate DH-S1P
resulted in the induction of neurotrophic factors and suppression of
inflammatory genes
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cytokines is mediated primarily by direct intracellular
effects [4, 11], which would not be subjected to receptor
downmodulation.
However, we demonstrated an involvement of surface
S1PR3 and to a lesser extent S1PR1. The involvement of
the S1PR1 is in line with an EAE model utilizing several
knockout approaches, where the therapeutic effect of
FTY720 was reported to be linked to S1P1R on astro-
cytes [23]. The important role of S1PR1 in EAE was
further strengthened by the finding that defective phos-
phorylation of S1PR1 exacerbated TH17-mediated auto-
immune neuroinflammation [62]. Our data indicate that






Fig. 6 Neurotrophic factors are induced by FTY-P via S1P receptor types 1 and 3. a Human U373 astrocytoma cells were treated with FTY-P
(1 μM) or S1P-receptor 1 (S1PR1) specific (SEW-2871, 1 and 10 μM), or S1P-receptor 3 (S1PR3) specific (CYM 5541, 1 and 10 μM), agonists and then
left untreated (left panel) or stimulated with TNF (0.025 μg/ml) 1 h later (right panel). Supernatants were harvested 16 h later, and LIF production
was detected by ELISA; mean ± SEM of three independent biological replicates. b Human U373 astrocytoma cells were pretreated with S1PR1 specific
(W146, 1 and 10 μM), or S1PR3 specific (TY52156, 1 and 10 μM) antagonists, stimulated with FTY-P (1 μM), and then left untreated (left panel) or
stimulated with TNF (0.025 μg/ml) 1 h later (right panel). Supernatants were harvested 16 h later, and LIF production was detected by ELISA; mean ±
SEM of three independent biological replicates. c, d Human U373 astrocytoma cells were transfected with a control siRNA or two different siRNAs
(2 nM) targeting S1PR1 and S1PR3, respectively, using Lipofectamine RNAimax. c Knock-down was validated by quantitative PCR; mean ± SEM of four
independent biological replicates. d Twenty-four hours after siRNA transfection, cells were stimulated with FTY-P (1 μM). Eight hours later, supernatants
were harvested, and LIF (left panel) and IL11 (right panel) production was determined by ELISA; representative experiment of four independent
biological replicates
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Summary
Taken together, we observed that FTY-P induced neuro-
trophic factors and blocked inflammatory cytokines in
astrocytes. These findings open the possibility that a part
of the beneficial effects of FTY720 could be mediated
via astrocytes.
Additional files
Additional file 1: Figure S1. Validation of different house-keeping
genes for quantitative PCR in human astrocytes or U373 astrocytoma
cells. Human astrocytes (A) or human U373 astrocytoma cells (B, C) were
stimulated with the indicated amounts of FTY-P or S1P, followed by
stimulation with TNF, when indicated. Eight hours later, cell lysates were
harvested and expression of the housekeeping genes GAPDH, beta-actin,
and PPIA (cyclophilin) was determined by quantitative PCR (mean ± SEM
of two (A) and three (B, C) independent biological replicates).
Additional file 2: Table S1. siRNA sequences. Sequences of the sense
strand of siRNAs targeting S1P1 and S1P3 are listed. All siRNAs are
Silencer® Select Validated siRNAs (Life Technologies).
Additional file 3: Table S2. Human primary astrocytes, stimulated with
FTY-P (left) or S1P (right) for 1 or 8 h and analyzed on an Illumina
microarray. Shown are genes with significant regulation with at least one
of the compounds (adjusted p value < 0.05, in bold print) at 1 h (upper
table) and 8 h (lower table). The list is sorted for fold-changes by FTY-P.
Additional file 4: Figure S2. Expression of LIFR, EGFR, and IL11RA on
human fetal neural progenitor cells. Fetal Striatal brain cells were
differentiated for 7 days (hstrNPCs) and analyzed by qPCR. For
comparison, human primary astrocytes (HA) are shown (mean ± SD of
two technical replicates).
Additional file 5: Figure S3. Analysis of possible interactions between
FTY-P and TNF. (A) Human U373 astrocytoma cells were stimulated with
FTY-P (1 μM) or S1P (1 μM), followed after 1 h by stimulation with TNF
(0.025 μg/ml) when indicated. Eight hours later, cell lysates were harvested
and expression of SPHK1, SPHK2, SGPL1, and SGPP1 was determined by
quantitative PCR (mean ± SEM of five independent biological replicates;
two-tailed paired t tests). (B) Human U373 astrocytoma cells were trans-
fected with a luciferase-based NFκB-reporter and stimulated with FTY-P
(1 μM) and TNF (0.025 μg/ml) 1 h later. Eight hours later, NFκB-activation was
determined (mean ± SEM of combined data of 8–11 independent biological
replicates). (C) FTY-P and S1P do not increase TNF receptor expression. Hu-
man primary astrocytes were treated with FTY-P, S1P, or vehicle control for 1
or 8 h (see Fig. 1, same microarray experiment). Normalized gene expres-
sion for TNFRSF1A (the main receptor for soluble TNF) and TNFRSF1B is dis-
played on the Y axis. Boxplots indicate median and first/third quartile, with
whiskers extending to outliers up to 1.5 × interquartile range.
Additional file 6: Figure S4. Human primary astrocytes and U373
astrocytoma cells mainly express S1P receptor types 1 and 3. Expression
of S1PR1-5 was determined in human primary astrocytes (A) and human
U373 astrocytoma cells (B) by qPCR (mean ± SD of two technical replicates).
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